Sensus Healthcare, Inc. (NASDAQ:SRTS) Short Interest Up 107.4% in December

Sensus Healthcare, Inc. (NASDAQ:SRTS) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,210,000 shares, an increase of 107.4% from the December 15th total of 583,500 shares. Currently, 9.2% of the company’s shares are sold short. Based on an average daily trading volume, of 203,100 shares, the days-to-cover ratio is currently 6.0 days.

Analyst Ratings Changes

A number of brokerages have recently commented on SRTS. HC Wainwright raised their target price on shares of Sensus Healthcare from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, November 18th. Maxim Group raised their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Friday, November 15th.

Sensus Healthcare Price Performance

NASDAQ SRTS traded down $0.04 on Thursday, reaching $6.73. The company had a trading volume of 136,249 shares, compared to its average volume of 219,665. Sensus Healthcare has a 1 year low of $2.61 and a 1 year high of $9.33. The firm has a 50-day moving average of $7.69 and a 200-day moving average of $6.71. The firm has a market capitalization of $110.30 million, a PE ratio of 11.81 and a beta of 1.21.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SRTS. Geode Capital Management LLC lifted its holdings in Sensus Healthcare by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock worth $849,000 after buying an additional 11,525 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Sensus Healthcare by 128.0% during the second quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock worth $888,000 after acquiring an additional 93,511 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Sensus Healthcare by 34.4% in the second quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock worth $2,087,000 after acquiring an additional 100,294 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Sensus Healthcare in the second quarter valued at about $156,000. Finally, Marshall Wace LLP grew its stake in Sensus Healthcare by 152.4% during the 2nd quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock valued at $412,000 after purchasing an additional 46,732 shares in the last quarter. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.